CMS Opens Door To More Compendium Oversight In Draft White Paper
Executive Summary
A draft white paper examining conflict of interest in the production of drug compendia appears to open the door for more oversight of the publications used for determining coverage of prescription drugs' off-label indications by Medicare and private insurers
You may also be interested in...
Compendia Conflict Of Interest White Paper A Precursor To New Regulations
Compendia publishers can expect to see new regulations regarding transparency and conflict of interest by the end of the year, and those rules could have an effect on whether a compendium will be recognized by CMS as a source for making coverage decisions for off-label drug uses
Compendia Conflict Of Interest White Paper A Precursor To New Regulations
Compendia publishers can expect to see new regulations regarding transparency and conflict of interest by the end of the year, and those rules could have an effect on whether a compendium will be recognized by CMS as a source for making coverage decisions for off-label drug uses
Insurers Call For Greater Transparency In Compendia Process
Third-party payers are looking for greater transparency in the processes that are used to generate compendia that list off-label uses of pharmaceuticals